A retrospective analysis of the incidence of clostridium difficile associated diarrhea with meropenem and piperacillin-tazobactam

International Journal of Collaborative Research on Internal Medicine and Public Health

Volumn 4, Issue 8, 2012, Pages 1567-1576

  Yeung, Eugene Y H ^a   Gore, Jason G ^a   Auersperg, Edward V ^a  

^a Ridge Meadows Hospital and Health Care Centre   (Canada)

Author keywords

Clostridium difficile; Diarrhea; Meropenem; Mortality; Piperacillin tazobactam; Saccharomyces boulardii

Indexed keywords

MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM DIFFICILE INFECTION ASSOCIATED DIARRHEA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK REDUCTION; SEX RATIO; TREATMENT DURATION;

EID: 84865370477     PISSN: 18404529     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Fekety R. Guidelines for the diagnosis and management of clostridium difficile-associated diarrhea and colitis. american college of gastroenterology, practice parameters committee. Am J Gastroenterol. 1997;92(5):739-750.
2. Lentino JR. Merck manual: Clostridium difficile-Induced diarrhea [online]. http://www.merck.com/mmpe/sec14/ch178/ch178d.html. Updated 2009 Aug 1. Accessed Dec 20, 2010.
3. Lowe MN, Lamb HM. Meropenem: An updated review of its use in the management of intra-abdominal infections. Drugs. 2000;60(3):619-646.
4. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: A beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007;5(3):365-383.
5. Compendium of Pharmaceuticals and Specialties, ed. Merrem product monograph. Mississauga (ON): AstraZeneca Inc; 2007 Feb 27.
6. Compendium of Pharmaceuticals and Specialties, ed. Tazocin product monograph. Markham (ON): Wyeth Canada; 2008 Aug 20.
7. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother. 2005;55(6):974-982.
8. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;54(1):168-172.
9. Alston WK, Ahern JW. Increase in the rate of nosocomial clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin. J Antimicrob Chemother. 2004;53(3):549-550.
10. Mendez MN, Gibbs L, Jacobs RA, McCulloch CE, Winston L, Guglielmo BJ. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and clostridium difficile infections. Pharmacotherapy. 2006;26(1):61-67.
11. Centers for Disease Control and Prevention (CDC). Severe clostridium difficile-associated disease in populations previously at low risk--four states, 2005. MMWR Morb Mortal Wkly Rep. 2005;54(47):1201-1205.
12. Koh TH, Tan AL, Tan ML, Wang G, Song KP. Epidemiology of clostridium difficile infection in a large teaching hospital in singapore. Pathology. 2007;39(4):438-442.
13. Manian FA, Aradhyula S, Greisnauer S, et al. Is it clostridium difficile infection or something else? A case-control study of 352 hospitalized patients with new-onset diarrhea. South Med J. 2007;100(8):782-786.
14. Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents. 2009;33 Suppl 1:S42-S45.
15. Buchner AM, Sonnenberg A. Epidemiology of clostridium difficile infection in a large population of hospitalized US military veterans. Dig Dis Sci. 2002;47(1):201-207.
16. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997;24(3):324-333.
17. Sharma AK, Holder FE. Clostridium difficile diarrhea after use of tacrolimus following renal transplantation. Clin Infect Dis. 1998;27(6):1540-1541.
18. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired clostridium difficile-associated disease. JAMA. 2005;294(23):2989-2995.
19. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Patterns of antibiotic use and risk of hospital admission because of clostridium difficile infection. CMAJ. 2008;179(8):767-772.
20. Settle CD, Wilcox MH, Fawley WN, Corrado OJ, Hawkey PM. Prospective study of the risk of clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther. 1998;12(12):1217-1223.
21. Jamal WY, Mokaddas EM, Verghese TL, Rotimi VO. In vitro activity of 15 antimicrobial agents against clinical isolates of clostridium difficile in kuwait. Int J Antimicrob Agents. 2002;20(4):270-274.
22. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther. 1986;39(5):489-490.
23. Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to clostridium difficile, clostridium perfringens, and staphylococcus aureus. J Clin Microbiol. 2006;44(8):2785-2791.
24. Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA. Risk factors for acquisition of clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol. 2005;26(8):680-684.
25. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhea by saccharomyces boulardii: A prospective study. Gastroenterology. 1989;96(4):981-988.
26. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol. 2009;15(13):1554-1580.
27. Peterson LR, Robicsek A. Does my patient have clostridium difficile infection? Ann Intern Med. 2009;151(3):176-179.